JP7702866B2 - Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート - Google Patents
Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート Download PDFInfo
- Publication number
- JP7702866B2 JP7702866B2 JP2021527836A JP2021527836A JP7702866B2 JP 7702866 B2 JP7702866 B2 JP 7702866B2 JP 2021527836 A JP2021527836 A JP 2021527836A JP 2021527836 A JP2021527836 A JP 2021527836A JP 7702866 B2 JP7702866 B2 JP 7702866B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- compound
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the nitrogen atom of at least one of the carboxamide groups further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/08—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with two six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
- C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Polymers & Plastics (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Materials Engineering (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025106091A JP2025138724A (ja) | 2018-11-20 | 2025-06-24 | Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769946P | 2018-11-20 | 2018-11-20 | |
| US62/769,946 | 2018-11-20 | ||
| PCT/US2019/062302 WO2020106780A1 (en) | 2018-11-20 | 2019-11-19 | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025106091A Division JP2025138724A (ja) | 2018-11-20 | 2025-06-24 | Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022507781A JP2022507781A (ja) | 2022-01-18 |
| JP2022507781A5 JP2022507781A5 (cg-RX-API-DMAC7.html) | 2022-11-29 |
| JP7702866B2 true JP7702866B2 (ja) | 2025-07-04 |
Family
ID=69005818
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021527836A Active JP7702866B2 (ja) | 2018-11-20 | 2019-11-19 | Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
| JP2025106091A Pending JP2025138724A (ja) | 2018-11-20 | 2025-06-24 | Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025106091A Pending JP2025138724A (ja) | 2018-11-20 | 2025-06-24 | Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
Country Status (20)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025138724A (ja) * | 2018-11-20 | 2025-09-25 | レゲネロン ファーマシューティカルス,インコーポレーテッド | Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3042428A1 (en) | 2016-11-08 | 2018-05-17 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
| KR20250008984A (ko) | 2017-05-18 | 2025-01-16 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| WO2019217591A1 (en) | 2018-05-09 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-msr1 antibodies and methods of use thereof |
| US12605459B2 (en) * | 2020-07-13 | 2026-04-21 | Regeneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
| MX2023004935A (es) | 2020-11-10 | 2023-07-07 | Regeneron Pharma | Conjugados de anticuerpos y selenio. |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| CA3224492A1 (en) | 2021-07-19 | 2023-01-26 | Xiaojun Han | Immunoconjugates and methods |
| CA3228214A1 (en) * | 2021-11-02 | 2023-05-11 | Changjiang Huang | Antibody-drug conjugate intermediate comprising sn38 and preparation method therefor |
| CN115594766A (zh) * | 2021-12-30 | 2023-01-13 | 辽宁键凯科技有限公司(Cn) | 一种缀合物及用其制备的抗体偶联药物 |
| CN115505028A (zh) * | 2022-09-16 | 2022-12-23 | 辽宁键凯科技有限公司 | 一种分支型聚乙二醇连接子及其用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003516327A (ja) | 1999-12-13 | 2003-05-13 | メルク エンド カムパニー インコーポレーテッド | アテローム性動脈硬化の予防および/または治療方法 |
| US20030125357A1 (en) | 2001-06-11 | 2003-07-03 | Adams Alan D. | Therapeutic compounds for treating dyslipidemic conditions |
| JP2017503847A (ja) | 2014-01-27 | 2017-02-02 | ファイザー・インク | 二官能性細胞毒性剤 |
| WO2018089373A2 (en) | 2016-11-08 | 2018-05-17 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| EP1398032A1 (en) | 2002-09-10 | 2004-03-17 | PheneX Pharmaceuticals AG | 4-Oxo-quinazolines as LXR nuclear receptor binding compounds |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| CA2570496A1 (en) | 2004-06-24 | 2006-01-05 | Galapagos N.V. | Methods and compositions to promote bone homeostasis |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| EP2121621B1 (en) | 2006-12-08 | 2014-05-07 | Exelixis Patent Company LLC | Lxr and fxr modulators |
| US8993628B2 (en) | 2007-02-23 | 2015-03-31 | City Of Hope | Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| US7985557B2 (en) | 2007-05-23 | 2011-07-26 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| UA108598C2 (xx) | 2008-04-30 | 2015-05-25 | Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери) | |
| KR101000067B1 (ko) | 2008-12-30 | 2010-12-10 | 엘지전자 주식회사 | 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법 |
| PT2528625E (pt) | 2010-04-15 | 2013-10-17 | Spirogen Sarl | Pirrolobenzodiazepinas e conjugados das mesmas |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| DK2714685T3 (en) | 2011-05-27 | 2017-01-09 | Ambrx Inc | FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| AU2012322934B2 (en) | 2011-10-14 | 2016-09-08 | Medimmune Limited | Pyrrolobenzodiazepines |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| JP6166728B2 (ja) | 2011-10-14 | 2017-07-19 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体 |
| CA2850375C (en) | 2011-10-14 | 2019-07-02 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| HRP20180268T4 (hr) | 2012-10-23 | 2026-03-27 | Synaffix B.V. | Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu |
| BR112016014126B1 (pt) | 2013-12-16 | 2023-02-14 | Medimmune Limited | Composto não-peptídico, conjugados de anticorpo-fármaco do mesmo, uso dos ditos conjugados para o tratamento de câncer e composição farmacêutica que compreende os mesmos |
| TWI871999B (zh) | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | 抗her3抗體-藥物結合物 |
| US20160324981A1 (en) | 2015-05-08 | 2016-11-10 | The California Institute For Biomedical Research | Liver x receptor agonists and uses thereof |
| CA3001938A1 (en) * | 2015-11-04 | 2017-05-11 | Borealis Ag | A process for producing a multilayer laminate |
| EP3419670A2 (en) | 2016-02-26 | 2019-01-02 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| EP3625209A1 (en) | 2017-05-18 | 2020-03-25 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof |
| WO2019217591A1 (en) | 2018-05-09 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-msr1 antibodies and methods of use thereof |
| CA3120528A1 (en) * | 2018-11-20 | 2020-05-28 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists |
-
2019
- 2019-11-19 CA CA3120528A patent/CA3120528A1/en active Pending
- 2019-11-19 IL IL283313A patent/IL283313B2/en unknown
- 2019-11-19 EA EA202191430A patent/EA202191430A1/ru unknown
- 2019-11-19 EP EP19827877.2A patent/EP3883926B1/en active Active
- 2019-11-19 CN CN201980089547.4A patent/CN113382985A/zh active Pending
- 2019-11-19 US US17/295,420 patent/US12209180B2/en active Active
- 2019-11-19 SG SG11202105175WA patent/SG11202105175WA/en unknown
- 2019-11-19 MA MA53455A patent/MA53455B1/fr unknown
- 2019-11-19 ES ES19827877T patent/ES2984190T3/es active Active
- 2019-11-19 JP JP2021527836A patent/JP7702866B2/ja active Active
- 2019-11-19 AU AU2019384136A patent/AU2019384136B2/en active Active
- 2019-11-19 WO PCT/US2019/062302 patent/WO2020106780A1/en not_active Ceased
- 2019-11-19 MX MX2021005822A patent/MX2021005822A/es unknown
- 2019-11-19 MY MYPI2021002708A patent/MY206542A/en unknown
- 2019-11-19 KR KR1020217018084A patent/KR20210094568A/ko active Pending
- 2019-11-19 EP EP24186656.5A patent/EP4428142A3/en active Pending
- 2019-11-19 BR BR112021009673A patent/BR112021009673A2/pt unknown
-
2021
- 2021-05-19 CL CL2021001308A patent/CL2021001308A1/es unknown
- 2021-05-20 ZA ZA2021/03431A patent/ZA202103431B/en unknown
- 2021-05-20 PH PH12021551153A patent/PH12021551153A1/en unknown
- 2021-06-10 CO CONC2021/0007581A patent/CO2021007581A2/es unknown
-
2024
- 2024-12-16 US US18/983,183 patent/US20250171622A1/en active Pending
-
2025
- 2025-06-24 JP JP2025106091A patent/JP2025138724A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003516327A (ja) | 1999-12-13 | 2003-05-13 | メルク エンド カムパニー インコーポレーテッド | アテローム性動脈硬化の予防および/または治療方法 |
| US20030125357A1 (en) | 2001-06-11 | 2003-07-03 | Adams Alan D. | Therapeutic compounds for treating dyslipidemic conditions |
| JP2017503847A (ja) | 2014-01-27 | 2017-02-02 | ファイザー・インク | 二官能性細胞毒性剤 |
| WO2018089373A2 (en) | 2016-11-08 | 2018-05-17 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
Non-Patent Citations (6)
| Title |
|---|
| COLIN M TICE,THE MEDICINAL CHEMISTRY OF LIVER X RECEPTOR (LXR) MODULATORS,JOURNAL OF MEDICINAL CHEMISTRY,2014年09月11日,VOL:57, NR:17,,PAGE(S):7182 - 7205,http://dx.doi.org/10.1021/jm500442z |
| COLIN, M. T. et al.,THE MEDICINAL CHEMISTRY OF LIVER X RECEPTOR (LXR) MODULATORS,JOURNAL OF MEDICINAL CHEMISTRY,2014年09月11日,Vol.57, No.17,pp.7182 - 7205,DOI:10.1021/jm500442z |
| SINGH S B,DISCOVERY AND DEVELOPMENT OF DIMERIC PODOCARPIC ACID LEADS AS POTENT AGONISTS OF LIVER X RECEPTOR WITH HDL CHOLESTEROL RAISING ACTIVITY IN MICE AND HAMSTERS,BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,NL,PERGAMON,2005年06月02日,VOL:15, NR:11,,PAGE(S):2824 - 2828,http://doi.org/10.1016/j.bmcl.2005.03.100 |
| SINGH S B,DISCOVERY AND DEVELOPMENT OF DIMERIC PODOCARPIC ACID LEADS AS POTENT AGONISTS 以下備考,BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,NL,PERGAMON,2005年06月02日,VOL:15, NR:11,,PAGE(S):2824 - 2828,http://doi.org/10.1016/j.bmcl.2005.03.100,OF LIVER X RECEPTOR WITH HDL CHOLESTEROL RAISING ACTIVITY IN MICE AND HAMSTERS |
| SINGH, S. B. et al.,DISCOVERY AND DEVELOPMENT OF DIMERIC PODOCARPIC ACID LEADS AS POTENT AGONISTS OF LIVER X RECEPTOR WITH HDL CHOLESTEROL RAISING ACTIVITY IN MICE AND HAMSTERS,BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,NL,PERGAMON,2005年06月02日,Vol.15, No.11,pp.2824 - 2828,DOI:10.1016/j.bmcl.2005.03.100 |
| SINGH, S. B. et al.,DISCOVERY AND DEVELOPMENT OF DIMERIC PODOCARPIC ACID LEADS AS POTENT AGONISTS OF LIVER X RECEPTOR WITH HDL CHOLESTEROL RAISING ACTIVITY IN MICE AND HAMSTERS,BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,PERGAMON,2005年06月02日,Vol.15, No.11,pp.2824 - 2828,DOI:10.1016/j.bmcl.2005.03.100 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025138724A (ja) * | 2018-11-20 | 2025-09-25 | レゲネロン ファーマシューティカルス,インコーポレーテッド | Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3883926B1 (en) | 2024-07-10 |
| CL2021001308A1 (es) | 2022-03-11 |
| MX2021005822A (es) | 2021-07-15 |
| EP4428142A3 (en) | 2024-11-20 |
| MY206542A (en) | 2024-12-20 |
| MA53455B1 (fr) | 2022-11-30 |
| AU2019384136A1 (en) | 2021-06-10 |
| IL283313B1 (en) | 2025-04-01 |
| KR20210094568A (ko) | 2021-07-29 |
| EP4428142A2 (en) | 2024-09-11 |
| PH12021551153A1 (en) | 2021-11-03 |
| IL283313B2 (en) | 2025-08-01 |
| JP2022507781A (ja) | 2022-01-18 |
| IL283313A (en) | 2021-07-29 |
| US20250171622A1 (en) | 2025-05-29 |
| CA3120528A1 (en) | 2020-05-28 |
| WO2020106780A1 (en) | 2020-05-28 |
| ES2984190T3 (es) | 2024-10-29 |
| CN113382985A (zh) | 2021-09-10 |
| MA53455A1 (fr) | 2021-12-31 |
| AU2019384136B2 (en) | 2024-06-06 |
| ZA202103431B (en) | 2024-09-25 |
| CO2021007581A2 (es) | 2021-06-21 |
| SG11202105175WA (en) | 2021-06-29 |
| EA202191430A1 (ru) | 2021-11-29 |
| US12209180B2 (en) | 2025-01-28 |
| JP2025138724A (ja) | 2025-09-25 |
| BR112021009673A2 (pt) | 2021-12-14 |
| EP3883926A1 (en) | 2021-09-29 |
| US20220080052A1 (en) | 2022-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7843731B2 (ja) | ビス-オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート | |
| JP2025138724A (ja) | Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート | |
| JP7426931B2 (ja) | 抗体薬物コンジュゲートのための親水性リンカー | |
| JP7617974B2 (ja) | シクロデキストリンタンパク質薬物コンジュゲート | |
| JP2025069133A (ja) | 無痕跡型リンカー及びそのタンパク質-コンジュゲート | |
| JP2021523147A (ja) | 抗msr1抗体及びその使用方法 | |
| JP7590328B2 (ja) | ツブリシン及びタンパク質-ツブリシンコンジュゲート | |
| JP2023533218A (ja) | ツブリシン及びタンパク質-ツブリシンコンジュゲート | |
| HK40116735A (en) | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof | |
| EA049882B1 (ru) | Производные бис-октагидрофенантренкарбоксамида и их белковые конъюгаты | |
| HK40060716A (en) | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists | |
| HK40060716B (en) | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists | |
| EA047045B1 (ru) | Бис-октагидрофенантрена карбоксамиды и их белковые конъюгаты |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210917 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221116 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221116 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231109 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240305 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240604 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240903 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241119 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250218 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250527 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250624 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7702866 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |